Lung Non-Squamous Non-Small Cell Carcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | c-Met >= 50% | Lung Non-Squamous Non-Small Cell Carcinoma | Telisotuzumab Vedotin | |
| FDA (1) | ERBB2 TKD activating variants | Lung Non-Squamous Non-Small Cell Carcinoma | Zongertinib | |
| FDA (1) | ERBB2 TKD activating variants | Lung Non-Squamous Non-Small Cell Carcinoma | Sevabertinib |